Restoring immune suppression in the multiple sclerosis brain

Progress in Neurobiology

Volumn 89, Issue 4, 2009, Pages 359-368

  Koning, Nathalie ^a,b   Uitdehaag, Bernard M J ^c   Huitinga, Inge ^a,d   Hoek, Robert M ^a,b  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NETHERLANDS BRAIN BANK   (Netherlands)

Author keywords

CD200 receptor; CNS; Macrophages; MS; Therapeutic target

Indexed keywords

BETA INTERFERON; CD200 ANTIGEN; CD200 RECEPTOR; CD47 ANTIGEN; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 3; GLATIRAMER; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MITOXANTRONE; MYELIN; NATALIZUMAB; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA; SIGNAL REGULATORY PROTEIN ALPHA AGONIST; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4 ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BONE MARROW CELL; CARDIOTOXICITY; CELL ACTIVATION; CELL MIGRATION; CELL POPULATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LEUKEMIA; LEUKOPENIA; LYMPHOCYTE FUNCTION; MACROPHAGE ACTIVATION; MICROGLIA ACTIVATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; RELAPSE; REVIEW; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES; ANTIGENS, CD; BRAIN; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; INTEGRIN ALPHA4BETA1; INTERFERON-BETA; MACROPHAGE-1 ANTIGEN; MACROPHAGES; MICROGLIA; MITOXANTRONE; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; MYELIN SHEATH; PEPTIDES;

EID: 70450225045     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2009.09.005     Document Type: Review

References (143)

1. Adams R.A., Bauer J., Flick M.J., Sikorski S.L., Nuriel T., Lassmann H., Degen J.L., and Akassoglou K. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med. 204 (2007) 571-582
2. Adams R.D., and Kubik C.S. The morbid anatomy of the demyelinative disease. Am. J. Med. 12 (1952) 510-546
3. Aharoni R., Eilam R., Domev H., Labunskay G., Sela M., and Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 19045-19050
4. Aharoni R., Teitelbaum D., Arnon R., and Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 634-639
5. Aharoni R., Teitelbaum D., Sela M., and Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10821-10826
6. Akiyama H., and McGeer P.L. Brain microglia constitutively express beta-2 integrins. J. Neuroimmunol. 30 (1990) 81-93
7. Almawi W.Y., Beyhum H.N., Rahme A.A., and Rieder M.J. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol. 60 (1996) 563-572
8. Banerjee D., and Dick A.D. Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats. Ocul. Immunol. Inflamm. 12 (2004) 115-125
9. Barkhof F., Thompson A.J., Hodgkinson S., Oeston B.V., Lai M., and Polman C.H. Double blind placebo controlled MRI monitored trial of chimeric anti CD4 antibodies in MS. J. Neuroimmunol. S1 (1995) 15
10. Baron J.L., Madri J.A., Ruddle N.H., Hashim G., and Janeway Jr. C.A. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177 (1993) 57-68
11. Bauer J., Huitinga I., Zhao W., Lassmann H., Hickey W.F., and Dijkstra C.D. The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 15 (1995) 437-446
12. Benveniste E.N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. 75 (1997) 165-173
13. Blanchette F., and Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J. Neurol. 255 Suppl. 1 (2008) 26-36
14. Blazar B.R., Lindberg F.P., Ingulli E., Panoskaltsis-Mortari A., Oldenborg P.A., Iizuka K., Yokoyama W.M., and Taylor P.A. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J. Exp. Med. 194 (2001) 541-549
15. Bornstein M.B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., Keilson M., Merriam A., Wassertheil-Smoller S., and Spada V. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317 (1987) 408-414
16. Boven L.A., Van Meurs M., Van Zwam M., Wierenga-Wolf A., Hintzen R.Q., Boot R.G., Aerts J.M., Amor S., Nieuwenhuis E.E., and Laman J.D. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129 (2006) 517-526
17. Breij E.C., Brink B.P., Veerhuis R., van den B.C., Vloet R., Yan R., Dijkstra C.D., Van D.V., and Bo L. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 63 (2008) 16-25
18. Broderick C., Hoek R.M., Forrester J.V., Liversidge J., Sedgwick J.D., and Dick A.D. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am. J. Pathol. 161 (2002) 1669-1677
19. Burger D., Molnarfi N., Weber M.S., Brandt K.J., Benkhoucha M., Gruaz L., Chofflon M., Zamvil S.S., and Lalive P.H. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 4355-4359
20. Butovsky O., Landa G., Kunis G., Ziv Y., Avidan H., Greenberg N., Schwartz A., Smirnov I., Pollack A., Jung S., and Schwartz M. Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis. J. Clin. Invest. 116 (2006) 905-915
21. Carmona O., Casado V., Moral E., onso-Magdalena L., Martinez-Yelamos A., Martinez-Yelamos S., Martin-Ozaeta G., and Arbizu T. Interferon-beta(1b) in multiple sclerosis: effect on progression of disability and clinical markers of treatment response. Eur. Neurol. 60 (2008) 279-284
22. Chitnis T., Imitola J., Wang Y., Elyaman W., Chawla P., Sharuk M., Raddassi K., Bronson R.T., and Khoury S.J. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am. J. Pathol. 170 (2007) 1695-1712
23. Comi G., Filippi M., and Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49 (2001) 290-297
24. Davis G.E. The Mac-1 and p150,95 beta 2 integrins bind denatured proteins to mediate leukocyte cell-substrate adhesion. Exp. Cell Res. 200 (1992) 242-252
25. de Vries H.E., Hendriks J.J., Honing H., de Lavalette C.R., van der Pol S.M., Hooijberg E., Dijkstra C.D., and van den Berg T.K. Signal-regulatory protein alpha-CD47 interactions are required for the transmigration of monocytes across cerebral endothelium. J. Immunol. 168 (2002) 5832-5839
26. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 23 (2009) 379-396
27. Dore-Duffy P., Washington R., and Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv. Exp. Med. Biol. 331 (1993) 243-248
28. Fabriek B.O., Van Haastert E.S., Galea I., Polfliet M.M., Dopp E.D., Van Den Heuvel M.M., van den Berg T.K., De Groot C.J., Van D.V., and Dijkstra C.D. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 51 (2005) 297-305
29. Fidler J.M., DeJoy S.Q., and Gibbons Jr. J.J. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J. Immunol. 137 (1986) 727-732
30. Fidler J.M., DeJoy S.Q., Smith III F.R., and Gibbons Jr. J.J. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J. Immunol. 136 (1986) 2747-2754
31. Floris S., Ruuls S.R., Wierinckx A., van der Pol S.M., Dopp E., van der Meide P.H., Dijkstra C.D., and de Vries H.E. Interferon-beta directly influences monocyte infiltration into the central nervous system. J. Neuroimmunol. 127 (2002) 69-79
32. Fridkis-Hareli M., and Strominger J.L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J. Immunol. 160 (1998) 4386-4397
33. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O.J., Brenner T., Arnon R., and Sela M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4872-4876
34. Gao H.M., and Hong J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. (2008)
35. Garden G.A., and Moller T. Microglia biology in health and disease. J. Neuroimmune Pharmacol. 1 (2006) 127-137
36. Ghalie R.G., Edan G., Laurent M., Mauch E., Eisenman S., Hartung H.P., Gonsette R.E., Butine M.D., and Goodkin D.E. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59 (2002) 909-913
37. Gordon S. Biology of the macrophage. J. Cell Sci. Suppl 4 (1986) 267-286
38. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3 (2003) 23-35
39. Graeber M.B., Streit W.J., and Kreutzberg G.W. Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J. Neurosci. Res. 21 (1988) 18-24
40. Graeber M.B., Tetzlaff W., Streit W.J., and Kreutzberg G.W. Microglial cells but not astrocytes undergo mitosis following rat facial nerve axotomy. Neurosci. Lett. 85 (1988) 317-321
41. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., and Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11 (2005) 328-334
42. Hanisch U.K., and Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10 (2007) 1387-1394
43. Hartung H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 8 (2009) 28-31
44. Hartung H.P., Gonsette R., Konig N., Kwiecinski H., Guseo A., Morrissey S.P., Krapf H., and Zwingers T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
45. Heppner F.L., Greter M., Marino D., Falsig J., Raivich G., Hovelmeyer N., Waisman A., Rulicke T., Prinz M., Priller J., Becher B., and Aguzzi A. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11 (2005) 146-152
46. Hickey W.F. Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol. 11 (1999) 125-137
47. Hickey W.F., and Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239 (1988) 290-292
48. Hoek R.M., Ruuls S.R., Murphy C.A., Wright G.J., Goddard R., Zurawski S.M., Blom B., Homola M.E., Streit W.J., Brown M.H., Barclay A.N., and Sedgwick J.D. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290 (2000) 1768-1771
49. Hofmann N., Lachnit N., Streppel M., Witter B., Neiss W.F., Guntinas-Lichius O., and Angelov D.N. Increased expression of ICAM-1, VCAM-1, MCP-1, and MIP-1 alpha by spinal perivascular macrophages during experimental allergic encephalomyelitis in rats. BMC Immunol. 3 (2002) 11
50. Huitinga I., Damoiseaux J.G., Dopp E.A., and Dijkstra C.D. Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats. Eur. J. Immunol. 23 (1993) 709-715
51. Huitinga I., Ruuls S.R., Jung S., Van Rooijen N., Hartung H.P., and Dijkstra C.D. Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin. Exp. Immunol. 100 (1995) 344-351
52. Huitinga I., Van Rooijen N., De Groot C.J., Uitdehaag B.M., and Dijkstra C.D. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172 (1990) 1025-1033
53. Hurst E.W. The effects of the injection of normal brain emulsion into rabbits, with special reference to the aetiology of the paralytic accidents of antirabic treatment. J. Hyg. 32 (1932) 33
54. Jenmalm M.C., Cherwinski H., Bowman E.P., Phillips J.H., and Sedgwick J.D. Regulation of myeloid cell function through the CD200 receptor. J. Immunol. 176 (2006) 191-199
55. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., and Schiffer R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
56. Jordan F.L., and Thomas W.E. Brain macrophages: questions of origin and interrelationship. Brain Res. 472 (1988) 165-178
57. Kharitonenkov A., Chen Z., Sures I., Wang H., Schilling J., and Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386 (1997) 181-186
58. Kiefer R., and Kreutzberg G.W. Effects of dexamethasone on microglial activation in vivo: selective downregulation of major histocompatibility complex class II expression in regenerating facial nucleus. J. Neuroimmunol. 34 (1991) 99-108
59. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353 (2005) 369-374
60. Koning N., Bo L., Hoek R.M., and Huitinga I. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann. Neurol. 62 (2007) 504-514
61. Koning N., Swaab D.F., Hoek R.M., and Huitinga I. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol. Exp. Neurol. 68 (2009) 159-167
62. Kotter M.R., Zhao C., Van R.N., and Franklin R.J. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol. Dis. 18 (2005) 166-175
63. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996) 312-318
64. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., and Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353 (2005) 375-381
65. Levine S., and Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J. Neuroimmunol. 13 (1986) 175-181
66. Lindberg F.P., Bullard D.C., Caver T.E., Gresham H.D., Beaudet A.L., and Brown E.J. Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science 274 (1996) 795-798
67. Lindsey J.W., Hodgkinson S., Mehta R., Mitchell D., Enzmann D., and Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 36 (1994) 183-189
68. Lublin F.D., Lavasa M., Viti C., and Knobler R.L. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol. Immunopathol. 45 (1987) 122-128
69. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., and Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004) 677-686
70. Marik C., Felts P.A., Bauer J., Lassmann H., and Smith K.J. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?. Brain 130 (2007) 2800-2815
71. Martin-Saavedra F.M., Gonzalez-Garcia C., Bravo B., and Ballester S. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol. Immunol. 45 (2008) 4008-4019
72. Mato M., Ookawara S., Sakamoto A., Aikawa E., Ogawa T., Mitsuhashi U., Masuzawa T., Suzuki H., Honda M., Yazaki Y., Watanabe E., Luoma J., Yla-Herttuala S., Fraser I., Gordon S., and Kodama T. Involvement of specific macrophage-lineage cells surrounding arterioles in barrier and scavenger function in brain cortex. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 3269-3274
73. Matyszak M.K., Lawson L.J., Perry V.H., and Gordon S. Stromal macrophages of the choroid plexus situated at an interface between the brain and peripheral immune system constitutively express major histocompatibility class II antigens. J. Neuroimmunol. 40 (1992) 173-181
74. Mayadas T.N., and Cullere X. Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol. 26 (2005) 388-395
75. McWhirter J.R., Kretz-Rommel A., Saven A., Maruyama T., Potter K.N., Mockridge C.I., Ravey E.P., Qin F., and Bowdish K.S. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 1041-1046
76. Meuth S.G., Simon O.J., Grimm A., Melzer N., Herrmann A.M., Spitzer P., Landgraf P., and Wiendl H. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J. Neuroimmunol. 194 (2008) 62-69
77. Mildner A., Schmidt H., Nitsche M., Merkler D., Hanisch U.K., Mack M., Heikenwalder M., Bruck W., Priller J., and Prinz M. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 10 (2007) 1544-1553
78. Millefiorini E., Gasperini C., Pozzilli C., D'Andrea F., Bastianello S., Trojano M., Morino S., Morra V.B., Bozzao A., Calo' A., Bernini M.L., Gambi D., and Prencipe M. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. 244 (1997) 153-159
79. Nakajima K., and Kohsaka S. Functional roles of microglia in the brain. Neurosci. Res. 17 (1993) 187-203
80. Neilley L.K., Goodin D.S., Goodkin D.E., and Hauser S.L. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 46 (1996) 552-554
81. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then B.F., Dose T., Wekerle H., and Hohlfeld R. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7452-7457
82. Neumann H., Kotter M.R., and Franklin R.J. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132 (2009) 288-295
83. Niino M., Bodner C., Simard M.L., Alatab S., Gano D., Kim H.J., Trigueiro M., Racicot D., Guerette C., Antel J.P., Fournier A., Grand'Maison F., and Bar-Or A. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. 59 (2006) 748-754
84. Nimmerjahn A., Kirchhoff F., and Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308 (2005) 1314-1318
85. Oldenborg P.A., Zheleznyak A., Fang Y.F., Lagenaur C.F., Gresham H.D., and Lindberg F.P. Role of CD47 as a marker of self on red blood cells. Science 288 (2000) 2051-2054
86. Owens T., Bechmann I., and Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 67 (2008) 1113-1121
87. Platten M., and Steinman L. Multiple sclerosis: trapped in deadly glue. Nat. Med. 11 (2005) 252-253
88. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., and Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 899-910
89. Polman C.H., and Uitdehaag B.M. Drug treatment of multiple sclerosis. BMJ 321 (2000) 490-494
90. Prineas J.W., and Graham J.S. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann. Neurol. 10 (1981) 149-158
91. Prineas J.W., and Wright R.G. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest. 38 (1978) 409-421
92. Prinz M., Schmidt H., Mildner A., Knobeloch K.P., Hanisch U.K., Raasch J., Merkler D., Detje C., Gutcher I., Mages J., Lang R., Martin R., Gold R., Becher B., Bruck W., and Kalinke U. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28 (2008) 675-686
93. Raivich G., and Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res. Brain Res. Rev. 46 (2004) 261-281
94. Ransohoff R.M. Natalizumab and PML. Nat. Neurosci. 8 (2005) 1275
95. Rao K.M. MAP kinase activation in macrophages. J. Leukoc. Biol. 69 (2001) 3-10
96. Rasmussen S., Wang Y., Kivisakk P., Bronson R.T., Meyer M., Imitola J., and Khoury S.J. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing-remitting experimental autoimmune encephalomyelitis. Brain 130 (2007) 2816-2829
97. Remlinger J. Accidents paralytiques au cours du traitment anti-rabique. Ann. Inst. Pasteur 19 (1905) 625
98. Ridge S.C., Sloboda A.E., McReynolds R.A., Levine S., Oronsky A.L., and Kerwar S.S. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin. Immunol. Immunopathol. 35 (1985) 35-42
99. Rijkers E.S., de R.T., Baridi A., Veninga H., Hoek R.M., and Meyaard L. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol. Immunol. 45 (2008) 1126-1135
100. Rivers T.M., Sprunt D.H., and Berry G.P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 58 (1933) 39
101. Rosen H., and Gordon S. Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo. J. Exp. Med. 166 (1987) 1685-1701
102. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., and Tuohy V.K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50 (1998) 1294-1300
103. Sackstein R. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr. Opin. Hematol. 12 (2005) 444-450
104. Sarchielli P., Orlacchio A., Vicinanza F., Pelliccioli G.P., Tognoloni M., Saccardi C., and Gallai V. Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. J. Neuroimmunol. 80 (1997) 76-86
105. Seitelberger F. Pathology of multiple sclerosis. Ann. Clin. Res. 5 (1973) 337-344
106. Sierra A., Gottfried-Blackmore A., Milner T.A., McEwen B.S., and Bulloch K. Steroid hormone receptor expression and function in microglia. Glia 56 (2008) 659-674
107. Smith M.E. Phagocytic properties of microglia in vitro: implications for a role in multiple sclerosis and EAE. Microsc. Res. Tech. 54 (2001) 81-94
108. Soilu-Hanninen M., Roytta M., Salmi A., and Salonen R. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J. Neuroimmunol. 72 (1997) 95-105
109. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
110. Sriram S., Carroll L., Fortin S., Cooper S., and Ranges G. In vivo immunomodulation by monoclonal anti-CD4 antibody. II. Effect on T cell response to myelin basic protein and experimental allergic encephalomyelitis. J. Immunol. 141 (1988) 464-468
111. Sriram S., and Roberts C.A. Treatment of established chronic relapsing experimental allergic encephalomyelitis with anti-L3T4 antibodies. J. Immunol. 136 (1986) 4464-4469
112. Sriram S., and Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology 48 (1997) 464-470
113. Stahn C., and Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pract. Rheumatol. 4 (2008) 525-533
114. Stapulionis R., Oliveira C.L., Gjelstrup M.C., Pedersen J.S., Hokland M.E., Hoffmann S.V., Poulsen K., Jacobsen C., and Vorup-Jensen T. Structural insight into the function of myelin basic protein as a ligand for integrin alpha M beta 2. J. Immunol. 180 (2008) 3946-3956
115. Stefanidakis M., Newton G., Lee W.Y., Parkos C.A., and Luscinskas F.W. Endothelial CD47 interaction with SIRP{gamma} is required for human T-cell transendothelial migration under shear flow conditions in vitro. Blood 112 (2008) 1280-1289
116. Steffen B.J., Butcher E.C., and Engelhardt B. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am. J. Pathol. 145 (1994) 189-201
117. Stuart G., and Krikorian K.S. The neuro-paralytic accidents of anti-rabies treatment. Ann. Trop. Med. Parasitol. 22 (1928) 327
118. Stuve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Hemmer B., Monson N.L., and Racke M.K. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59 (2006) 743-747
119. Teige I., Treschow A., Teige A., Mattsson R., Navikas V., Leanderson T., Holmdahl R., and Issazadeh-Navikas S. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 170 (2003) 4776-4784
120. Teitelbaum D., Arnon R., and Sela M. Copolymer 1: from basic research to clinical application. Cell Mol. Life Sci. 53 (1997) 24-28
121. Tischner D., and Reichardt H.M. Glucocorticoids in the control of neuroinflammation. Mol. Cell Endocrinol. 275 (2007) 62-70
122. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
123. Trebst C., Konig F., Ransohoff R., Bruck W., and Stangel M. CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult. Scler. 14 (2008) 728-733
124. Underhill D.M., Bassetti M., Rudensky A., and Aderem A. Dynamic interactions of macrophages with T cells during antigen presentation. J. Exp. Med. 190 (1999) 1909-1914
125. Valledor A.F., and Ricote M. Nuclear receptor signaling in macrophages. Biochem. Pharmacol. 67 (2004) 201-212
126. van Assche G., Van R.M., Sciot R., Dubois B., Vermeire S., Noman M., Verbeeck J., Geboes K., Robberecht W., and Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353 (2005) 362-368
127. van de Wyngaert F.A., Beguin C., D'Hooghe M.B., Dooms G., Lissoir F., Carton H., and Sindic C.J. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol. Belg. 101 (2001) 210-216
128. van der Laan L.J., Ruuls S.R., Weber K.S., Lodder I.J., Dopp E.A., and Dijkstra C.D. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J. Neuroimmunol. 70 (1996) 145-152
129. Van der Valk P., and De Groot C.J. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol. Appl. Neurobiol. 26 (2000) 2-10
130. van Rossum D., and Hanisch U.K. Microglia. Metab. Brain Dis. 19 (2004) 393-411
131. van Rossum D., Hilbert S., Strassenburg S., Hanisch U.K., Bruck W., and 't Hart B.A. Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype. Glia 56 (2008) 271-283
132. Verbeek M.M., Westphal J.R., Ruiter D.J., and de Waal R.M. T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4/vascular cell adhesion molecule-1 interactions. J. Immunol. 154 (1995) 5876-5884
133. Walker D.G., Dalsing-Hernandez J.E., Campbell N.A., and Lue L.F. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp. Neurol. 215 (2009) 5-19
134. Watson C.M., Davison A.N., Baker D., O'Neill J.K., and Turk J.L. Suppression of demyelination by mitoxantrone. Int. J. Immunopharmacol. 13 (1991) 923-930
135. Weber M.S., Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., Patarroyo J.C., Stuve O., Sobel R.A., Steinman L., and Zamvil S.S. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13 (2007) 935-943
136. Weinstock-Guttman B., Badgett D., Patrick K., Hartrich L., Santos R., Hall D., Baier M., Feichter J., and Ramanathan M. Genomic effects of IFN-beta in multiple sclerosis patients. J. Immunol. 171 (2003) 2694-2702
137. Wright G.J., Cherwinski H., Foster-Cuevas M., Brooke G., Puklavec M.J., Bigler M., Song Y., Jenmalm M., Gorman D., McClanahan T., Liu M.R., Brown M.H., Sedgwick J.D., Phillips J.H., and Barclay A.N. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J. Immunol. 171 (2003) 3034-3046
138. Wright G.J., Jones M., Puklavec M.J., Brown M.H., and Barclay A.N. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 102 (2001) 173-179
139. Wright G.J., Puklavec M.J., Willis A.C., Hoek R.M., Sedgwick J.D., Brown M.H., and Barclay A.N. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13 (2000) 233-242
140. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., and Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356 (1992) 63-66
141. Yong V.W., Chabot S., Stuve O., and Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51 (1998) 682-689
142. Zhang S., Cherwinski H., Sedgwick J.D., and Phillips J.H. Molecular mechanisms of CD200 inhibition of mast cell activation. J. Immunol. 173 (2004) 6786-6793
143. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2008) 178-201